MLYS - CIK 0001933414
Mineralys Therapeutics, Inc. trades as MLYS and has a market capitalization of $1.97 B, making it the #2107 largest US-listed company by market value. This page tracks Mineralys Therapeutics, Inc. through 350 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider sale notice | 144 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-06 |
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) :: Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) :: Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update :: Mineralys Therapeutics, Inc. (MLYS)
The largest companies sharing Mineralys Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $1.97 B as of 2026-06-10, ranking #2107 among US-listed companies.
In its latest fiscal year Mineralys Therapeutics, Inc. reported a net loss of $154.65M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.